CK Life Sciences (0775) announced that it has signed a distribution agreement with Biolidics Limited of Singapore to distribute a serology-based 10-minute rapid detection kit for Covid-19. The signing of the Biolidics agreement enables CK Life Sciences to offer two types of testing methodologies for Covid-19 in Hong Kong. Biolidics’ easy-to-use Rapid Detection Kit detects IgM/IgG antibodies against SARS-CoV-2 in 10 minutes, using serum, plasma or whole blood samples, with an accuracy of more than 95 percent when validated against clinical diagnosis of Covid-19. The Rapid Detection Kit has received provisional authorization from Singapore’s Health Sciences Authority as well as approval from the Food and Drug Administration of the Philippines. In addition, it is completing a listing process with the US FDA, for distribution, marketing, and sales to healthcare institutions.

Source: The Standard April 15, 2020 11:05 UTC